Posted by Michael Wonder on 04 Jun 2025
Cellectar granted US FDA breakthrough therapy designation for iopofosine I 131 in Waldenstrom macroglobulinemia
4 June 2025 - Designation supported by CLOVER WaM Phase 2 study data which reported an 83.6% overall response rate.
Cellectar Biosciences today announced that the US FDA has granted breakthrough therapy designation for iopofosine I 131, a potential first in class, novel cancer targeting agent utilising a phospholipid ether as a radio-conjugate monotherapy, for the treatment of relapsed/refractory Waldenstrom macroglobulinaemia.
